NASDAQ:IMGN
ImmunoGen Stock News
$31.23
+0 (+0%)
At Close: May 07, 2024
ImmunoGen (IMGN) Enters New Collaboration to Boost ADC Pipeline
11:36am, Tuesday, 14'th Jun 2022
ImmunoGen (IMGN) inks a collaboration deal with privately-held Oxford BioTherapeutics to develop novel antibody-drug conjugates by complementing each other's proprietary technologies.
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
04:30pm, Wednesday, 25'th May 2022
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review
01:39pm, Tuesday, 24'th May 2022 Zacks Investment Research
ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.
ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review
11:18am, Tuesday, 24'th May 2022
ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.
What's Going On With ImmunoGen Shares Today?
12:40pm, Monday, 23'rd May 2022
ImmunoGen, Inc. (NASDAQ: IMGN) shares are trading flat at $3.57 after the company's Biologics License Application to treat ovarian cancer was accepted by the FDA with priority review. ImmunoGen's BLA
ImmunoGen's stock is up 12% after the FDA accepts application for new ovarian-cancer therapy
07:59am, Monday, 23'rd May 2022
Shares of ImmunoGen Inc. IMGN, +1.42% jumped 12.0% in premarket trading on Monday after the company said the Food and Drug Administration accepted an application for its experimental ovarian-cancer tr
ImmunoGen: An Inflection Point In Growth
04:16pm, Tuesday, 17'th May 2022
ImmunoGen is a promising turnaround equity that is approaching its inflection point in growth. Mirvetuximab is poised to gain approval toward yearend.
ImmunoGen (IMGN) Q1 Earnings and Sales Outpace Estimates
03:21pm, Monday, 09'th May 2022 Zacks Investment Research
ImmunoGen (IMGN) reports a narrower-than-expected loss for first-quarter 2022. It also beats revenue estimates.
ImmunoGen (IMGN) Q1 Earnings and Sales Outpace Estimates
12:47pm, Monday, 09'th May 2022
ImmunoGen (IMGN) reports a narrower-than-expected loss for first-quarter 2022. It also beats revenue estimates.
ImmunoGen (IMGN) Q1 2022 Earnings Call Transcript
05:30pm, Friday, 06'th May 2022 The Motley Fool
IMGN earnings call for the period ending March 31, 2022.
ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q1 2022 Results - Earnings Call Transcript
01:12pm, Friday, 06'th May 2022
ImmunoGen, Inc. (NASDAQ:IMGN ) Q1 2022 Results Conference Call May 6, 2022 8:00 AM ET Company Participants Courtney O'Konek - Senior Director, Corporate Communications Mark Enyedy - President, CEO Ann
ImmunoGen (IMGN) Reports Q1 Loss, Tops Revenue Estimates
11:45am, Friday, 06'th May 2022 Zacks Investment Research
ImmunoGen (IMGN) delivered earnings and revenue surprises of 52.38% and 56.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen (IMGN) Reports Q1 Loss, Tops Revenue Estimates
09:03am, Friday, 06'th May 2022
ImmunoGen (IMGN) delivered earnings and revenue surprises of 52.38% and 56.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen: Way Beyond SORAYA
10:35am, Sunday, 10'th Apr 2022
The market recently discounted ImmunoGen due to its expectation of Mirvetuximab's SORAYA data.
Is ImmunoGen Stock a Bargain After Dropping 39%?
03:23pm, Friday, 01'st Apr 2022 The Motley Fool
It takes more than a price drop to make a bargain.
